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Background: Genome-wide association studies and candidate-gene based approaches have identified multiple
common variants associated with increased risk of sudden cardiac death (SCD). However, the independent con-
tribution of these individual loci to disease risk is modest.
Objective: To investigate the cumulative effects of genetic variants previously associated with SCD risk.
Methods: A total of 966 SCD cases from the Oregon-Sudden Unexpected Death Study and 1926 coronary artery
disease controls from the Wellcome Trust Case–Control Consortium were investigated. We generated genetic
risk scores (GRSs) for each trait composed of variants previously associated with SCD or with abnormalities in
specific electrocardiographic traits such as QRS duration, QTc interval and heart rate. GRSs were calculated
using a weighted approach based on the number of risk alleles weighted by the beta coefficients derived from
the original studies. We also compared the highest and lowest quintiles for the GRS composed of SCD SNPs.
Results: Increased cumulative riskwas observed for a GRS composed of 14 SCD-SNPs (OR=1.17 [1.05–1.29], P=
0.002). The risk for SCDwas 1.5 fold greater in the highest risk quintilewhen compared to the lowest risk quintile
(OR = 1.46 [1.11–1.92]). We did not observe significant associations with SCD for SNPs that determine electro-
cardiographic traits.
Conclusions: Amodest but significant effect on SCD risk was identified for a GRS composed of 14 previously asso-
ciated SCD SNPs. While next generation sequencing methodology will continue to identify additional novel var-
iants, these findings represent proof of concept for the additive effects of gene variants on SCD risk.
© 2015 The Authors. Published by Elsevier Ireland Ltd.This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sudden cardiac death (SCD) is a major public health problem respon-
sible formore than 300,000 deaths in the United States on an annual basis
[1–3]. Implantable defibrillators are effective in treatingmalignant tachy-
arrhythmias but their impact in primary prevention of SCD could be sig-
nificantly enhanced by improvements in risk stratification [4–7]. Earlynome-wide association studies;
xpectedDeath Study; SCD, sud-
onsortium.
Suite A3100, 127 S San Vicente
8, United States. Tel.: +1 310
land Ltd.This is an open access article ustudies highlighting a genetic contribution to pathophysiology of SCD
[8–11] prompted multiple candidate-gene based studies and genome
wide association studies (GWAS) [12,13]. As a result, several new loci as-
sociated with increased risk of SCD were identified from candidate gene
based studies [14–20]. From GWAS studies, DNA variants within the
BAZ2B [21] and CXADR [22] loci have passed the stringent GWAS signifi-
cance threshold. However, independently, most of these loci contribute
modestly to disease risk. In this study, we selected and investigated the
contribution of common variants associated with SCD by published
GWAS and candidate gene approaches.We also evaluated variants associ-
ated with intermediate electrical phenotypes (endophenotypes), specifi-
cally QRS duration [23], heart rate [24] and QTc interval [25]. We
hypothesized that a genetic risk score (GRS) comprised of genetic variants
that had been previously associated with SCD or SCD electricalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 2
Association of GRS with SCD associated phenotypes.
966 cases/1926 controlsa 668 cases/1926 controlsb
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To test this, we developed GRSs for each of these endophenotypes and
tested their association with SCD, using a well characterized SCD sample
from the Oregon Sudden Unexpected Death Study (Oregon-SUDS). As
controls, we used subjects with coronary artery disease (CAD) from the
Wellcome Trust Case Control Consortium Study (WTCCC), thus looking
for variants that influence risk of SCD in individuals with CAD, constitut-
ing the most common form of SCD.
2. Methods
2.1. Ethics statement
This study was approved by the Institutional Review Boards of the
Oregon Health and Science University, Cedars-Sinai Medical Center
and all participant hospitals. The WTCCC Data Access Committee ap-
proved the use of the WTCCC data. All samples have been analyzed in
accordance with the principles expressed in the Declaration of Helsinki.
Written informed consent was obtained from all enrolled subjects.
2.2. Subjects
2.2.1. Oregon-SUDS
A total of 966 SCD cases of European descent from the Oregon-SUDS
[26–28] with GWAS data available, were included in the study. The
Oregon-SUDS is an ongoing prospective study of out-of-hospital SCD.
Methods have been published in detail [26,28]. Briefly, SCD cases were
identified from the emergency medical response system, the medical
examiner network and 16 local hospitals. All available medical records
were obtained for each subject following the SCD event, providing a de-
tailed lifetime clinical history for the purpose of phenotyping. SCD was
defined as an unexpected pulseless condition of likely cardiac origin. If
unwitnessed, SCD was defined as unexpected death within 24 h of
having last been seen alive and in a normal state of health [3]. CAD
was defined as 50% stenosis of amajor coronary artery, physician report
of past myocardial infarction (MI), history of percutaneous coronary in-
tervention (PCI) or coronary artery bypass grafting (CABG); autopsy-
identified CAD or MI by clinical data with any two of the following
three: ischemic symptoms, positive troponins or CKMB; or pathologic
Q waves on ECG. SCD cases with chronic terminal illnesses, known
non-cardiac causes of SCD, traumatic deaths and drug overdose were
excluded from the analysis.
2.2.2. WTCCC subjects
A total of 1926 coronary artery disease (CAD) subjectswere included
as the comparison (control) group. We used CAD subjects rather than
population controls due to the significant overlap between SCD and
CAD (CAD is diagnosed in at least 80% of overall SCD cases) [29]. This
wouldmaximize the chances of developing a GRS that would be specific
for SCD. CAD status and diagnosiswas validated by direct review of clin-
ical notes. All subjectswere ofWhite European origin and further details
of the WTCCC subjects were previously reported [30].
2.2.3. Genotyping and SNP selection
The Oregon-SUDs cases and the WTCCC controls were genotyped
and imputed separately using Affymetrix 6.0 and 500 K arraysTable 1
Traits included for the genetic risk scores estimations.
Traits No. of SNPs Reference
SCDa 14 14–22
QRS duration 24 23
Heart rate 19 24
QTc interval 9 25
a Sudden cardiac death.respectively. SNPs were selected based on information obtained from
the NHGRI GWAS Catalogue [31] and literature review [14–25]. We se-
lected 55 independent SNPs previously identified in GWAS studies for
SCD-related phenotypes with P = 5 × 10−8, these include: QRS dura-
tion, QT interval, and heart rate. (Table 1 and Supplementary Table 1).
We also included 14 SNPs associated with SCD in previous GWAS and
candidate gene studies [14–22]. Deviation from Hardy Weinberg equi-
librium was not observed for any SNP in either cases or controls.
Three SNPs with minor allele frequency less than 5% were excluded
from further analyses. After quality control, 66 SNPs for the 4 traits
were included. For imputed SNPs, we used the posterior continuous
values between 0 and 2. A complete list of the investigated variants is
provided in Supplementary Table 1.
2.2.4. Statistical analysis
Separate GRSs were developed for SNPs previously associated with
increased risk of SCD (14 SNPs), prolonged QRS duration (26 SNPs),
QT interval (9 SNPs) and increased heart rate (18 SNPs). For each of
these GRSs, a weighted GRS was calculated for each individual based
on the number of risk alleles weighted by the standardized beta coeffi-
cients derived from the original GWAS studies. Genetic risk scores were
tested for association by using logistic regression models implement in
Golden Helix SNP and Variation Suite (Golden Helix, Bonzeman, MT,
USA). The status (case–control) was used as the outcome variable and
the GRS as the predictor variable. In addition, we analyzed associations
between individuals in the lowest and highest quintiles for the GRS
composed of SCD SNPs using logistic regression. Individuals in the
highest quintile were classified as high risk. Analyses were adjusted
for age and gender.
3. Results
The mean ages of the subjects in the Oregon-SUDS and the WTCCC
studies were 60.3 ± 9.4 and 49.7 ± 12.8 years respectively. Seventy
two percent of SCD cases and 79.2% of CAD controls were male. SCD
cases were relatively older than CAD controls and therefore we per-
formed analyses using the complete sample size in the Oregon-SUDs
(n= 966) as well as a sample size restricted to the same age range ob-
served in WTCCC (n = 668); similar results were observed (Table 2).
3.1. Genetic risk score associations
We investigated association of each of the weighted GRS in the
merged Oregon-SCD cases and WTCCC CAD control dataset including
a total of 2892 unrelated individuals.
The cumulative effects of 14 common variants previously involved
in SCD was modestly associated with an increased risk (OR = 1.17,
P= 0.002). The results remained significant after adjusting for multiple
testing comparisons. The risk for SCDwas 1.5 fold greater in the highest
risk quintile when compared to the lowest risk quintile (OR = 1.46
[1.11–1.92]). Two DNA variants within Calsequestrin 2 (CASQ2),Phenotype N SNPs OR (95% CI)c P-value OR (95% CI)c P-value
Heart rate 18 0.59 [0.24–1.41] 0.23 0.56 [0.22–1.41] 0.22
QTc interval 9 1.01 [0.49–2.09] 0.69 0.86 [0.36–2.01] 0.73
QRS duration 26 1.04 [0.87–1.24] 0.65 1.06 [0.88–1.27] 0.51
SCDd 14 1.17 [1.05–1.29] 0.002 1.16 [1.05–1.29] 0.003
a Results including 966 SCD cases and 1926 controls from the WTCCC.
b Results including a subset of 668 SCD cases (age range 26–67 years) and 1926 controls
from theWTCCC.
c OR indicates Odds ratio (95% confidence interval) per weighted allele increase in the
GRS for each investigated trait. Data was adjusted by age and gender.
d Sudden cardiac death.
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rs6730157 were individually associated with SCD risk (P b 0.05). We
did not observe significant associations for the GRS for SCD after includ-
ing these SNPs as covariates. As an exploratory analysis, we also evalu-
ated the cumulative risk of the two significantly associated SCD SNPs in
this study, resulting in an increased risk for SCD (OR–2.43, P =
5.18 × 10−10). The direction of the effect for rs3010396 within CASQ2
and rs6730157within RAB3GAP1was consistent with previous findings
[17,18].Wedid not observe evidence for amultiplicative interaction be-
tween SNPs rs3010396 and rs6730157 along with the main effects
(P = 0.57).
No evidence for associationwas observedwith SCD for SNPs that de-
termine electrocardiographic traits (Table 2).4. Discussion
We evaluated cumulative risk of SCD by computing GRSs based on
SNPs previously associated with SCD and SCD electrocardiographic
endophenotypes (heart rate [32], QTc interval [33] and QRS duration)
[34]. The contribution of other commonDNA variants previously associ-
ated with SCD was also evaluated. The predictive properties of these
GRSs were estimated in a well characterized SCD population-based
study from the Oregon-SUDS and CAD individuals fromWTCCC. No ev-
idence for association was found between the genetic risk score for the
three electrocardiographic traits and SCD risk. This is in linewith the ev-
idence from previous observations. A recent study conducted in the
Finnish population showed an association between common QTc inter-
val variants and SCD, but no significant linear relationship between the
genetic risk score for QTc interval and SCD was observed [35]. Although
the Finnish study was conducted in large population-based cohorts,
only 116 SCD cases were included.
The evaluation of the cumulative effects of common variants
associated with SCD showed a modest increase in SCD risk (OR =
1.17 [1.05–1.29], P–0.002). We observed that two SNPs (rs3010396
and rs6730157) were individually associated with SCD (P b 0.05). The
results did not remain significant after adjusting for rs3010396 and
rs6730157. This finding suggests that the genetic risk score for SCD
was principally driven by SNPs rs3010396 and rs6730157. Interestingly,
the combination of two common SNPs within CASQ2 and RAB3GAP1
significantly increased the odds for SCD risk (OR = 2.43, P =
7.41× 10−10). It is important to note that both SNPswere previously as-
sociated with an increased risk of SCD using a subset of SCD cases from
the Oregon-SUDS and CAD individuals as the comparison group [17,18].
What is the significance of these modest cumulative effects of pub-
lished common variants, on risk of SCD? Clearly, the relatively small
size of these effects is not likely tomake a significant impact on the pro-
cess of SCD risk stratification. In current clinical practice, the vastmajor-
ity of SCD risk assessment is carried out using clinical criteria. In most
patients the only clinical criterion is the measurement of the left ven-
tricular ejection fraction, now recognized to be inadequate as a risk as-
sessment tool [3,36]. Therefore given the current modest state of SCD
risk prediction and its overall impact on SCD prevention, it remains im-
portant to pursue the potential contributions of genetic testing to SCD
risk stratification. As a proof of concept, we opted to assess the potential
for cumulative effects on risk, of the multiple SNPs that were associated
with SCD from GWAS and candidate-gene based approaches. This will
also offer the possibility of combining clinical and genetic assessment
to improve SCD risk stratification. There are several factors to suggest
that our current analysis is likely to represent the first, albeit somewhat
crude attempt at making this assessment. Candidate gene based ap-
proaches and GWAS have significant limitations as tools for compre-
hensive and unbiased identification of gene variants, and next
generation sequencing approaches are designed to resolve these limita-
tions. Therefore, with the help of current tools, we are likely to identify a
more complete list of relevant SCD-associated gene variants.The large majority of SCD occurs in individuals who are currently
assessed as being at low or moderate risk. The question is, are we
using the right tools for risk assessment? While this is a difficult ques-
tion to answer at present, one of the potential tools could be a more
complete identification of genetic variation using next generation se-
quencing in patients who are classified based on subset of risk. It
would be particularly important to evaluate patients that were original-
ly deemed to be low or moderate risk. This aspect highlights the poten-
tially important role for studies like the present one that can identify
these apparently low tomoderate risk subsets, but all of them eventual-
ly suffered SCD. Another important aspect relates to the need for more
intensive phenotyping in larger populations of patients who have suf-
fered SCD. While a complete discussion is beyond the scope of this
paper, it is likely that a step-wise approachwill be needed. For example,
identification of high-risk subjects in a community study or cohort
study would lead to development of risk scores which in turn would
be tested in prospective long term follow-up studies of defibrillators
patients, in order to develop clinically useful risk scores. For genetic
assessment, next generation genotyping needs to be performed and
compared in high-risk population subsets of SCD based on intensive
phenotyping. The expanding networks of SCD investigation will make
it possible to identify these subgroups of enriched phenotypes. This
will also offer the possibility of combining clinical and genetic assess-
ment to improve SCD risk stratification.
Several limitations of the present study need to be considered. The
sample size is small compared with the discovery GWAS studies and
therefore lower statistical powermay account for the absence of associ-
ation observed for the investigated traits. The possibility remains that
the investigated variants included in this study are not the actual causal
variants. Also, we cannot exclude the potential confounding of electrical
phenotypemeasurements by prescription or othermedications. Finally,
wewere unable to test these same GRSs in a different populationwith a
comparable level of detailed phenotyping and therefore these findings
should be validated in additional populations.
In conclusion, we present proof of concept of the additive effect of
gene variants on risk of SCD. A modest but significant association was
found for the GRS composed of 14 previously associated SCD SNPs iden-
tified by GWAS. Next generation sequencing studies in larger samples of
well-phenotyped subjects, are likely going to be needed for the identifi-
cation of a clinically relevant cumulative genetic risk score for SCD.
Supplementary data to this article can be found online at http://dx.
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